NanoViricides, Inc. (NNVC) - Q1 2026 Form 10-Q Summary
Business Context and Reporting Period
NanoViricides, Inc. is a clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral drugs using a host-mimicry nanomedicine platform. The company operates in a single reportable segment: life science. This report covers the quarterly period ended September 30, 2025 (Fiscal Q1 2026). The company has no commercial products and generates no revenue, relying on equity financing and grants to fund research and development (R&D).
Key Financial Metrics
| Metric | Q1 2026 (Ended Sept 30, 2025) | Q1 2025 (Ended Sept 30, 2024) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,785,058) | $(3,126,811) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.23) |
| Operating Expenses | $1,796,685 | $3,167,834 |
| Cash and Cash Equivalents (End of Period) | $1,125,711 | $3,866,289 |
| Net Cash Used in Operating Activities | $(1,593,855) | $(2,594,863) |
| Total Current Liabilities | $1,182,386 | $1,306,519 |
| Stockholders' Equity | $7,174,694 | $10,107,791 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $1.37 million (43%) compared to the prior year quarter.
- Research & Development: Decreased by $940,025 to $993,066, primarily due to reduced outside lab fees for clinical studies.
- General & Administrative: Decreased by $431,124 to $803,619, driven by lower professional fees for investor outreach.
- Improved Loss Profile: Net loss narrowed by approximately $1.34 million year-over-year, resulting in a lower loss per share.
- Cash Position: Cash and cash equivalents declined by $432,853 during the quarter, ending at $1.13 million. This is a significant decrease from the $3.87 million balance in the prior year period.
- Financing Activity: The company raised approximately $1.25 million in net proceeds from the sale of common stock via its At-The-Market (ATM) program during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Despite raising approximately $6 million in subsequent financing (ATM and registered direct offering) between October and November 2025, management believes current resources are insufficient to fund planned operations.
- Clinical Milestones:
- NV-387 (Lead Candidate): Phase Ia/Ib human clinical trial for safety and tolerability was completed with no adverse events. The company is awaiting the final Clinical Study Report (CSR).
- MPox Phase II: Received final approval from ACOREP (DRC) to initiate a Phase II clinical trial for MPox treatment. Manufacturing of drug substance for this trial is complete.
- Measles & Respiratory Viruses: Completed animal studies for Measles. Planning Phase II trials for Viral Acute Respiratory Infections (V-ARI) in India.
- Subsequent Financing: In November 2025, the company closed a registered direct offering and ATM sales raising approximately $6 million gross (approx. $5.5 million net), including the issuance of pre-funded warrants and Series A/B warrants to an institutional investor.
- Related Party Transactions: Significant liabilities exist to related parties (TheraCour and KMPL), totaling approximately $901,000 in accounts payable. The company relies on TheraCour for technology licensing and manufacturing support.
- Risks: The company has no approved drugs, no revenue, and an accumulated deficit of $150.6 million. Continued operations depend on securing additional non-dilutive funding (grants/contracts) or equity/debt financing.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $6 million raised in November 2025 against the company's burn rate and the specific costs of the upcoming MPox Phase II trial.
- Related Party Exposure: Review the terms of the $901k payable to related parties (TheraCour/KMPL) and the dependency on these entities for IP and clinical execution.
- Regulatory Status: Confirm the receipt and content of the final Phase I Clinical Study Report for NV-387 and the timeline for the MPox Phase II initiation in the DRC.
- Dilution Impact: Assess the dilution from the recent registered direct offering, including the 1.97 million shares sold and the 3.57 million Series A and 3.57 million Series B warrants issued.
- Going Concern Mitigation: Monitor for further equity raises or non-dilutive grant announcements to address the substantial doubt expressed in the filing.